Nvidia beat its own forecast. A Fed official sees more hikes by spring. Salesforce led a software slide.

THE NUMBER

$400 million.

That is the most HarbourVest Global Private Equity will spend on a tender its holders approved. About 90% of votes were in favor. It is a London-listed fund of private equity investments. It will buy back its own shares for cash. The offer closes Nov. 19. The price is based on net asset value at Sept. 30, less 10%.

Holders who tender get cash without waiting for the fund to sell.

PREMIER FEATURE

Wall Street May Be Chasing Yesterday's AI Winners

While everyone watches the biggest AI names stumble, a new group of companies could be emerging as tomorrow's biggest winners.

Click here to learn more

THE SETUP
  • Nvidia (NVDA) reported $115.8 billion in quarterly sales. Its own forecast was $108 billion. It guided to $130 billion for this quarter, which has an extra week. The stock rose about 3% in after-hours trading, after closing down less than 0.5%. The S&P 500 closed down 1.0%, and the Dow fell 1.6%.
  • St. Louis Fed President Alberto Musalem said the economy will likely need several rate hikes before next spring. That goes further than Jefferson and Collins went in remarks Friday and Saturday. Musalem does not vote this year. The 10-year yield ended near 5.10%.
  • October retail sales rose 0.2%, after 0.8% in September. Sales excluding cars and gas rose 0.5%.
  • Salesforce (CRM) fell about 9.5%, leading other large software stocks lower.
IN FOCUS

Two Buyout Firms Filled Their Funds in Months. One Could Point to Recent Exits.

Gemspring Capital closed its fourth buyout fund at its $3.5 billion hard cap. It took one close and less than three months. The firm said its own partners are the largest single investor. Blue Sea Capital raised $800 million for health care, against a $550 million target. That topped its original $700 million cap.

Blue Sea raised its fund in four months. The firm said its exits this year totaled about $1.5 billion of enterprise value. That includes its first continuation vehicle. Cash coming back is what fund investors most want from a manager now. A single close also let Gemspring skip the usual months of rolling closes. When partners commit more than any outside investor, it can be read as a sign of conviction.

Cash Back Buys the Next Fund

For fund investors, this suggests that money flows to managers who have already returned cash. Fees and deal capacity are at stake for firms that cannot point to exits. Our read is that the market is splitting, with quick closes for proven managers and slower ones for the rest. Fast closes for managers without recent exits would weaken that read. More tenders like HarbourVest's would strengthen it.

FROM OUR PARTNERS

Ticker Revealed: Pre-IPO Access to the "Next Elon Musk" Company

We’ve found The Next Elon Musk… and what we believe to be the next Tesla.

It’s already racked up $26 billion in government contracts.

Peter Thiel just bet $1 Billion on it.

And you can get exposure — pre-IPO — through a 4-letter ticker symbol revealed in this free briefing.

Unlock the ticker now and get it completely free.

SIGNALS IN MOTION

SIGNAL 1: CVC Says It Won't Complete Its IRCA Purchase. Advent Says the Deal Is Binding.

CVC Capital Partners said it won't complete its purchase of IRCA. The seller is Advent International. IRCA is an Italian maker of pastry, chocolate and ice-cream ingredients. The deal was valued at nearly €3 billion. CVC pointed to its review of information it got in due diligence. It has not said what that review found.

Advent said CVC is pulling out of a signed, binding agreement. Neither side has described a break fee or the terms under which a buyer may walk. Nothing public shows the agreement has been formally ended.

WHAT RESOLVES THIS

For buyout investors, a signed sale is meant to be the sure part of an exit. Money is at stake because a walk-away can make later buyers ask for tougher terms and lower prices. One reading is a dispute about one deal; another is that buyers are looking harder for ways to reprice. A formal claim from Advent, or detail from CVC on what it found, would show which.

SIGNAL 2: Kenmare's Suitor Got Four More Weeks to Bid or Walk Away.

Ireland's Takeover Panel gave IRH more time to decide on a bid for Kenmare Resources. IRH is an Abu Dhabi group. It must now make a firm offer, or say it won't, by Dec. 15. The old deadline was Nov. 17.

Kenmare's board asked for the extension so IRH can carry out due diligence. No price has been disclosed.

WHAT RESOLVES THIS

For Kenmare holders, a board that asks for more time suggests both sides are still talking. The catch is that an extension is not an offer, so whether a bid comes, and at what price, moves to mid-December. The deadline could be extended again with Kenmare's support. Only a firm offer would settle the price question.

SIGNAL 3: Brookfield and KKR Are Vying for a Gulf Retailer. The Deal Reportedly Hinges on the War.

Brookfield (BAM) and KKR (KKR) are vying to buy control of Eyewa, a Gulf eyewear chain. That is according to a weekend report citing people familiar with the talks. The deal would value Eyewa at about $700 million. Any agreement is said to depend on the regional conflict not getting worse. No party has confirmed the talks.

Eyewa runs about 250 stores. Both bidders have built dedicated capacity in the region.

WHAT RESOLVES THIS

For buyout investors, money raised for a region has to be spent there, and sizable Gulf targets are scarce. The catch is a war clause, which ties the deal to events neither bidder controls. A signing would show the bidders judge the conflict contained. A delay would suggest the clause is doing its work.

PARTNER SPOTLIGHT

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)

"I want to give you a free stock pick today. This company's sales are up 28% year over year. It holds over 30,000 patents in wireless and video technology. And it just earned an A-rating in my proprietary Stock Grader system. That's the same system that helped me flag Nvidia back in 2005 — before its 82,000% run. In fact, this system has identified the top-performing S&P 500 stock for 12 years running. Over the years, it has cost me $9 million to build and maintain. And right now, it's flashing its highest possible rating on this AI play." — Louis Navellier Click here to see which AI stock my $9 million system is flagging right now, free.

This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.

WHAT MOST WILL MISS
  • Polymarket's Nov. 30 Iran "ceasefire" contract hit 79.5 cents early Tuesday. It was 68.5 on Monday and eased to about 75 cents by late Tuesday. Its rules pay after 14 days without a U.S. strike on Iran, with or without a deal. The jump came as only about $5,800 traded in a day.
  • U.S. spot bitcoin funds took in about $7.9 million Monday. That ended seven sessions of outflows worth about $1.91 billion. Bitcoin was near $64,000 after the U.S. close.
THE CROSSOVER

Private Market Trends Driving Public Market Moves

Money Came In Fast. Finishing Deals Took Longer.

Gemspring and Blue Sea filled their funds in months. Blue Sea could point to its exits. HarbourVest's holders approved a tender of up to $400 million. CVC says it won't complete a signed purchase, and Kenmare's suitor got four more weeks. A reported Gulf buyout hangs on the war. Public markets added a cost. Musalem sees several more hikes as likely, and the 10-year sat near 5.1%. Our read is that money goes first to managers who can show exits. Higher rates make the next exit harder to price. A firm Kenmare offer would ease that. More buyers walking after signing would deepen it.

On the calendar...

When

Event

Wed., Nov. 18

Fed minutes; Getty equity committee hearing; Anthropic pricing expected

Thu., Nov. 19

HarbourVest tender closes; Anthropic expected to begin trading

Tue.-Wed., Dec. 8-9

Fed meeting

Tue., Dec. 15

Kenmare deadline for IRH

AI Found the Target. AI Designed the Drug. Now It's in Phase III.

For years, AI drug discovery had a problem. Plenty of models. Very few medicines.
That's changing. One company says AI identified the biological target and then designed the molecule to hit it. In September, the first patient in its Phase III trial was dosed.
It isn't alone. A second AI-engineered medicine is in Phase III, and Big Pharma is now paying for the technology.
We profiled the 5 companies pushing AI into real drug development in a new FREE Special Report: AI Moves Into the Biotech Lab.
We'll text it straight to your phone.

Get the Free Report by Text →